Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
NCT03850769Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and tegafur in pancreatic adenocarcinoma (PDAC), sponsored by Peking Union Medical College Hospital. Primary endpoint: R0 resection rate at 3 years. Status: unknown.
02
Drugs
paclitaxeltegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03850769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850769.